About Agendia
Agendia is a company based in Irvine (United States) founded in 2003 by Laura van 't Veer. Agendia has raised $123 million across 7 funding rounds from investors including ING, Debiopharm and European Union. Agendia offers products and services including MammaPrint and BluePrint. Agendia operates in a competitive market with competitors including Guardant Health, Foundation Medicine, ArcherDX, Natera and Strand Life Sciences, among others.
- Headquarter Irvine, United States
- Founders Laura van 't Veer
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Agendia, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$123 M (USD)
in 7 rounds
-
Latest Funding Round
$4.7 M (USD), Grant
Dec 31, 2018
-
Investors
ING
& 10 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Agendia
Agendia offers a comprehensive portfolio of products and services, including MammaPrint and BluePrint.
Assesses breast cancer recurrence risk using genomic analysis.
Determines molecular subtyping of breast cancer tumors for treatment guidance.
People of Agendia
Unlock access to complete
Unlock access to complete
Funding Insights of Agendia
Agendia has successfully raised a total of $123M across 7 strategic funding rounds. The most recent funding activity was a Grant round of $4.7 million completed in December 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Agendia
Agendia has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include ING, Debiopharm and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Global private equity investments are managed by the firm.
|
Locked | Locked | Locked | |
|
Private equity and venture captial firm focused on healthcare sectors
|
Locked | Locked | Locked | |
|
Life-Sciences & Offline focused VC firm funding companies in Netherlands
|
Locked | Locked | Locked |
Investor details for Agendia
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Agendia
Investment portfolio details for Agendia
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Agendia
Detailed financials for Agendia
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Agendia Comparisons
Peer comparison for Agendia
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Agendia
Agendia operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, Foundation Medicine, ArcherDX, Natera and Strand Life Sciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery
|
|
| Locked | Locked | Locked |
Health risks are identified through online genetic and diagnostic testing.
|
Detailed competitors of Agendia
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Agendia
Complete news archive for Agendia
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Agendia
Agendia was founded in 2003 and raised its 1st funding round 2 years after it was founded.
Agendia is headquartered in Irvine, United States. It is registered at Irvine, California, United States.
Agendia is a funded company, having raised a total of $123M across 7 funding rounds to date.
Founded in 2003 and based in Irvine, United States, genomic diagnostic products for oncology are developed and supplied by Agendia. Breast cancer and solid tumors are analyzed through the flagship MammaPrint test. Tumor genes are subtyped into Luminal, HER2, and Basal categories via the BluePrint molecular test. Clinical trials in oncology are supported by the FLEX platform and I-SPY2 initiative.
Agendia's top competitors include Guardant Health, Strand Life Sciences and Foundation Medicine.
Agendia offers MammaPrint and BluePrint.
Agendia has 11 investors. Key investors include ING, Debiopharm, European Union, AXA Investment Managers, and Athyrium Capital Management.